Send mail to Author

Correction : phase I clinical study of the recombinant antibody-toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomas (Article)

Please indicate your contact information and select, which author you want to contact.



 
 _    _     ______   _    _    _    _    _    _     ______  
| || | ||  /_   _// | |  | || | || | || | |  | ||  /_   _// 
| || | ||   -| ||-  | |/\| || | || | || | |/\| ||   -| ||-  
| \\_/ ||   _| ||_  |  /\  || | \\_/ || |  /\  ||   _| ||_  
 \____//   /_____// |_// \_||  \____//  |_// \_||  /_____// 
  `---`    `-----`  `-`   `-`   `---`   `-`   `-`  `-----`
 


Back to frontdoor view

OPUS4 Logo